Oncology drugs
101 results
Abecma (idecabtagene vicleucel)
(idecabtagene vicleucel)Celgene Corporation
Usage: ABECMA is indicated for adult patients with relapsed or refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. It is a genetically modified autologous T cell immunotherapy targeting B-cell maturation antigen (BCMA).
Actimmune (interferon gamma-1b)
(Interferon gamma-1b)Horizon Therapeutics USA, Inc.
Usage: ACTIMMUNE is indicated for reducing the frequency and severity of serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in those with severe, malignant osteopetrosis (SMO).
Adcetris (brentuximab vedotin)
(brentuximab vedotin)SEAGEN INC.
Usage: ADCETRIS is indicated for treating previously untreated or relapsed Classical Hodgkin Lymphoma (cHL), Systemic Anaplastic Large Cell Lymphoma (sALCL), and relapsed or refractory Large B-Cell Lymphoma (LBCL) in adults, often in combination with chemotherapy. It is also approved for pediatric high-risk cHL.
Adstiladrin (nadofaragene firadenovec-vncg)
(nadofaragene firadenovec-vncg)Ferring Pharmaceuticals
Usage: ADSTILADRIN® is indicated for treating adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) that includes carcinoma in situ (CIS) with or without papillary tumors.
Akynzeo (netupitant and palonosetron)
(Netupitant and Palonosetron)Helsinn Therapeutics (U.S.), Inc.
Usage: AKYNZEO is indicated, in combination with dexamethasone, for the prevention of acute and delayed nausea and vomiting in adults undergoing initial and repeat courses of highly emetogenic cancer chemotherapy. It combines palonosetron for acute prevention and netupitant (or fosnetupitant in injection form) for both acute and delayed prevention.
Alecensa (alectinib hydrochloride)
(ALECTINIB HYDROCHLORIDE)Genentech, Inc.
Usage: ALECENSA is indicated for adjuvant treatment of resected ALK-positive non-small cell lung cancer (NSCLC) in adults and for the treatment of metastatic ALK-positive NSCLC in adults, both as detected by an FDA-approved test.
Alunbrig (brigatinib)
(brigatinib)Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as confirmed by an FDA-approved test.
Aphexda (motixafortide)
(Motixafortide)BioLineRx USA Inc
Usage: APHEXDA is indicated for use with filgrastim (G-CSF) to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Aromasin (exemestane)
(exemestane)Pharmacia & Upjohn Company LLC
Usage: AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after 2-3 years of tamoxifen, completing a total of 5 years of therapy. It is also used for advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Augtyro (repotrectinib)
(repotrectinib)E.R. Squibb & Sons, L.L.C.
Usage: AUGTYRO is indicated for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with locally advanced or metastatic solid tumors harboring NTRK gene fusions that have progressed after treatment or lack alternatives.
- ...